Miracle shampoos and hair loss in Panama: what Minsa requires

In Panama, hair loss is a common reason for consultation and a market for products that promise to stop it. On July 3, 2026, Panamá América published the position of the Panamanian Dermatology Association (APD): without a prior diagnosis, "miracle" shampoos and self-medication can worsen the scalp¹. This article puts that warning in context for physicians: what evidence supports topical treatments, where cosmetic peptides fit, and what the Dirección Nacional de Farmacia y Drogas (DNFD) of the Ministry of Health (Minsa) requires for a product to be sold as a cosmetic. It is regulatory and evidence analysis, not a recommendation for use.

What the Panamanian Dermatology Association said

According to the Panamá América piece, written with AI collaboration and quoting no named physicians, the APD says that telling temporary loss from female-pattern alopecia takes "a detailed blood test and digital trichoscopy in the office"¹. The article lists hormonal causes (postpartum, menopause, polycystic ovary syndrome), telogen effluvium from stress, surgery or trauma, iron, zinc, biotin or B and D vitamin shortfalls, thyroid disorders, and damage from heat or tight hairstyles¹.

Among treatments it names topical minoxidil "in concentrations adapted for women", guided supplementation, platelet-rich plasma (PRP) and low-level laser phototherapy, and urges consulting qualified specialists before any "empirical" treatment¹. The piece cites no studies and does not mention peptides¹.

What evidence supports topical treatment

The first step is the diagnosis. A 2026 review in Cleveland Clinic Journal of Medicine notes that telogen effluvium is usually reversible, that diagnosis is mainly clinical, and that management centers on identifying triggers and reassuring the patient⁹. An open randomized trial of 100 women with acute telogen effluvium (a lotion with creatine, acetyl tetrapeptide-2 and B vitamins versus mild shampoo alone) found an anagen/telogen ratio significantly higher than baseline at weeks 4 and 8 and significantly lower telogen hair density than controls at week 8; controls also improved by week 16, and the study was open-label and from a dermocosmetic company¹⁰.

In androgenetic alopecia the topical standard remains minoxidil: in 393 men, 5% was significantly better than 2% and placebo on hair count at 48 weeks¹¹. That trial was in men; the APD text speaks of concentrations "adapted for women", and adjusting them is the dermatologist's call¹¹¹. A 2025 meta-analysis of four trials and 279 patients found no difference in hair density or diameter between oral and topical minoxidil, with more hypertrichosis on the oral form¹², and another meta-analysis found low-dose oral minoxidil did not significantly change blood pressure, though heart rate rose¹³. These are prescription drugs; they are not cosmetics.

Hair peptides: what exists and what is missing

A 2026 systematic review in the Journal of Drugs in Dermatology included 14 studies out of 981 identified and gave a grade B recommendation to formulations with acetyl tetrapeptide-3, biotinoyl tripeptide-1, glycyl-histidyl-lysine (GHK) peptide and a pentapeptide, and grade C to QR678¹⁴. A 32-subject trial compared a combination of biochanin A, acetyl tetrapeptide-3 and ginseng with 3% minoxidil for 24 weeks: comparable efficacy, with terminal-hair increases of 8.3% and 8.7%¹⁷. With a complex of 5-aminolevulinic acid and GHK, 45 patients with male-pattern hair loss showed higher hair-count gains than placebo at the 50 mg/ml concentration (significant ratio difference)¹⁶. The copper work is more basic: AHK-Cu stimulated elongation of human hair follicles ex vivo and dermal papilla cells in culture¹⁸.

The counterpoint comes from a 2025 review of Redensyl, Procapil, Capixyl, Baicapil and other popular hair actives: studies have limited samples, no comparison with standard therapies, non-uniform groups, no disclosure of the alopecia type and conflicts of interest; its authors see them at most as add-on therapy or an alternative for patients who cannot tolerate standard care¹⁵. In short: none of these sources supports a peptide shampoo replacing a diagnosis.

Cosmetic or drug: what sanitary registration requires

Panamá Digital describes the Sanitary Registration Certificate for cosmetics and medicated cosmetics as the document that allows the product to be imported and sold nationwide, processed before the DNFD under Decreto 178 of 2001⁵. For a legal entity the list includes the qualitative and quantitative formula, labels, finished-product specifications, a certificate of free sale, a good manufacturing practice certificate, product studies, endorsement from the Colegio Nacional de Farmacéuticos and an original sample⁵. The page does not define "medicated cosmetic"; that line is worth checking with the DNFD before describing a hair product in therapeutic language⁵. Cosmetic registration was digitized in 2022 with the National Authority for Government Innovation (AIG), after being manual and in person³.

Registration is not permanent. On February 27, 2026, Infobae reported that a resolution in the Gaceta Oficial suspended sanitary registration 207839 of the Aquavera cleansing balm and ordered all lots withdrawn, after a report to the Pharmacovigilance Department of one case of "numbness of the tongue and blurred vision after using the product"; the importer, Dany S.A., had to file a report within 30 days². The article gives no lots and does not say whether the case was independently confirmed². In July the DNFD cancelled the registrations of two Britney Spears perfumes (resolutions 097 and 098 of June 24, 2026) and two Nivea sunscreens over BMHCA, a substance in Annex II of the EU cosmetics regulation, following a European Commission Safety Gate alert⁶⁷. On September 1, Uriel Pérez confirmed "multiple cancellations of sanitary registrations of medicines and cosmetics" in 2026, without figures⁴.

What physicians can do

• Document the diagnosis (blood test, trichoscopy) before attributing a change to any product, as the APD proposes¹⁹.
• Check a cosmetic's sanitary registration number and whether the label promises therapeutic effects; when in doubt, ask the DNFD⁵.
• Report a suspected reaction: on September 15, 2026 the DNFD launched the VigiMedic Panamá (medicines) and VigiVac Panamá (vaccines) apps, open to professionals and patients; the release does not say they cover cosmetics, so the route for a cosmetic should be confirmed with the DNFD⁸. The Aquavera case reached the DNFD through a report sent by email².

To see the same framework applied to other beauty products, see GHK-Cu creams: evidence and cosmetic registration, the BMHCA registration cancellations, peptides and hair loss and pharmacovigilance in Panama.